Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.72 |
| ▸ | HTR3A | P46098 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | KDM1A | O60341 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848360 | 0.91 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL26668494 | 0.87 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL2301711 | 0.86 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL13837634 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL3159146 | 0.83 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL3244911 | 0.82 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL796789 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL3605627 | 0.81 | MET (0.52) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL1475614 | 0.80 | TDP1 (0.70) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL16787789 | 0.80 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | SLC6A2 1187/4885SLC6A4 1110/4885SLC6A3 782/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | SLC6A2 1244/4885SLC6A4 1407/4885SLC6A3 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.